XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. acquires and develops pharmaceutical products for autoimmune diseases in Israel.
Lead drug candidate hCDR1 is Phase II-ready for treating systemic lupus erythematosus and Sjogrens syndrome.
The company has a licensing agreement with Yeda Research and Development Company Limited.
hCDR1 is being researched, developed, and commercialized for various indications.
The company was formerly known as Xenograft Technologies Ltd. until July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993.
Headquartered in Ramat Gan, Israel.
Overview
Strengths
- Creates economic value: ROIC of 100.0% against a cost of capital (WACC) of 5.7%, a spread of 94.3 percentage points.
- ROIC of 100.0% beats 93% of its 128 Biotechnology peers (median 0.0%).
- Skin in the game: insiders own 21% of the shares, aligning management with shareholders.
Weaknesses
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 20.2% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Tight liquidity: current liabilities exceed current assets (current ratio 0.40).
Key Financial Data